⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15962731 | 0.60 | SOS1 (0.39) | — | |
| SCHEMBL13414745 | 0.58 | L3MBTL1 (0.37) | — | |
| SCHEMBL8746989 | 0.58 | — | — | |
| SCHEMBL16790491 | 0.58 | — | — | |
| SCHEMBL15431974 | 0.55 | KDM4E (0.34) | — | |
| SCHEMBL562149 | 0.55 | — | — | |
| SCHEMBL16360895 | 0.54 | — | — | |
| SCHEMBL14154426 | 0.54 | CYP1A2 (0.37) | — | |
| SCHEMBL14820463 | 0.54 | — | — | |
| SCHEMBL1109076 | 0.53 | KDM4E (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3489238-B1 | PHARMACEUTICAL COMPOSITIONS OF 6H-PYRIDO[3,2-E][1,2,4]TRIAZOLO[1,5-C]PYRIMIDIN-5-ONE AND [1,2,4]TRIAZOLO[1,5-C]PTERIDIN-5(6H)-ONE DERIVATIVES AS PDE1 INHIBITORS FOR TREATING E.G. NEUROLOGICAL DISORDERS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2021-10-13 | — | — | EP | claimed |
| EP-3489238-A1 | PHARMACEUTICAL COMPOSITIONS OF 6H-PYRIDO[3,2-E][1,2,4]TRIAZOLO[1,5-C]PYRIMIDIN-5-ONE AND [1,2,4]TRIAZOLO[1,5-C]PTERIDIN-5(6H)-ONE DERIVATIVES AS PDE1 INHIBITORS FOR TREATING E.G. NEUROLOGICAL DISORDERS | Dart NeuroScience (Cayman) Ltd (KY) | 2019-05-29 | — | — | EP | claimed |
| EP-2861603-B1 | 6-Benzyl-6H-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one and 6-benzyl-[1,2,4]triazolo[1,5-c]pteridin-5(6H)-one derivatives as PDE1 inhibitors for treating e.g. neurological disorders | DART NEUROSCIENCE CAYMAN LTD (KY) | 2018-12-19 | — | — | EP | claimed |
| US-9284335-B2 | Substituted pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidines, pyrido[2,3-e][1,2,4]triazolo[1,5-c]pyrimidines and/or [1,2,4]triazolo[1,5-c]pteridines for treatment of central nervous system diseases and disorders | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2016-03-15 | — | — | US | claimed |
| US-20150158885-A1 | SUBSTITUTED PYRIDINE AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS | DART NEUROSCIENCE LLC | 2015-06-11 | — | — | US | claimed |
| EP-3489238-B1 | PHARMACEUTICAL COMPOSITIONS OF 6H-PYRIDO[3,2-E][1,2,4]TRIAZOLO[1,5-C]PYRIMIDIN-5-ONE AND [1,2,4]TRIAZOLO[1,5-C]PTERIDIN-5(6H)-ONE DERIVATIVES AS PDE1 INHIBITORS FOR TREATING E.G. NEUROLOGICAL DISORDERS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2021-10-13 | — | — | EP | disclosed |
| EP-3489238-A1 | PHARMACEUTICAL COMPOSITIONS OF 6H-PYRIDO[3,2-E][1,2,4]TRIAZOLO[1,5-C]PYRIMIDIN-5-ONE AND [1,2,4]TRIAZOLO[1,5-C]PTERIDIN-5(6H)-ONE DERIVATIVES AS PDE1 INHIBITORS FOR TREATING E.G. NEUROLOGICAL DISORDERS | Dart NeuroScience (Cayman) Ltd (KY) | 2019-05-29 | — | — | EP | disclosed |
| EP-2861603-B1 | 6-Benzyl-6H-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one and 6-benzyl-[1,2,4]triazolo[1,5-c]pteridin-5(6H)-one derivatives as PDE1 inhibitors for treating e.g. neurological disorders | DART NEUROSCIENCE CAYMAN LTD (KY) | 2018-12-19 | — | — | EP | disclosed |
| US-9284335-B2 | Substituted pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidines, pyrido[2,3-e][1,2,4]triazolo[1,5-c]pyrimidines and/or [1,2,4]triazolo[1,5-c]pteridines for treatment of central nervous system diseases and disorders | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2016-03-15 | — | — | US | disclosed |
| US-20150158885-A1 | SUBSTITUTED PYRIDINE AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS | DART NEUROSCIENCE LLC | 2015-06-11 | — | — | US | disclosed |